Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less

Authors: Ji Hyun Kwon, Yu Jung Kim, Keun-Wook Lee, Do-Youn Oh, So Yeon Park, Jee Hyun Kim, Eui Kyu Chie, Sung-Won Kim, Seock-Ah Im, In-Ah Kim, Tae-You Kim, In Ae Park, Dong-Young Noh, Yung-Jue Bang, Sung Whan Ha

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Whether a systemic adjuvant treatment is needed is an area of controversy in patients with node-negative early breast cancer with tumor size of ≤1 cm, including T1mic.

Methods

We performed a retrospective analysis of clinical and pathology data of all consecutive patients with node-negative T1mic, T1a, and T1b invasive ductal carcinoma who received surgery between Jan 2000 and Dec 2006. The recurrence free survival (RFS) and risk factors for recurrence were identified.

Results

Out of 3889 patients diagnosed with breast cancer, 375 patients were enrolled (T1mic:120, T1a:93, T1b:162). Median age at diagnosis was 49. After a median follow up of 60.8 months, 12 patients developed recurrences (T1mic:4 (3.3%), T1a:2 (2.2%), T1b:6 (3.7%)), with a five-year cumulative RFS rate of 97.2%. Distant recurrence was identified in three patients. Age younger than 35 years (HR 4.91; 95% CI 1.014-23.763, p = 0.048) and triple negative disease (HR 4.93; 95% CI 1.312-18.519, p = 0.018) were significantly associated with a higher rate of recurrence. HER2 overexpression, Ki-67, and p53 status did not affect RFS.

Conclusions

Prognosis of node-negative breast cancer with T1mic, T1a and T1b is excellent, but patients under 35 years of age or with triple negative disease have a relatively high risk of recurrence.
Appendix
Available only for authorised users
Literature
1.
Otto SJ, Fracheboud J, Looman CW, Broeders MJ, Boer R, Hendriks JH, Verbeek AL, de Koning HJ: Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet. 2003, 361 (9367): 1411-1417. 10.1016/S0140-6736(03)13132-7.CrossRefPubMed
2.
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005, 353 (17): 1784-1792. 10.1056/NEJMoa050518.CrossRefPubMed
3.
Duijm LE, Groenewoud JH, Roumen RM, de Koning HJ, Plaisier ML, Fracheboud J: A decade of breast cancer screening in The Netherlands: trends in the preoperative diagnosis of breast cancer. Breast Cancer Res Treat. 2007, 106 (1): 113-119. 10.1007/s10549-006-9468-5.CrossRefPubMed
4.
Son BH, Kwak BS, Kim JK, Kim HJ, Hong SJ, Lee JS, Hwang UK, Yoon HS, Ahn SH: Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15 years. Arch Surg. 2006, 141 (2): 155-160. 10.1001/archsurg.141.2.155.CrossRefPubMed
5.
Ahn SH: Clinical characteristics of breast cancer patients in Korea in 2000. Arch Surg. 2004, 139 (1): 27-30. 10.1001/archsurg.139.1.27. discussion 31CrossRefPubMed
6.
Joensuu H, Pylkkanen L, Toikkanen S: Late mortality from pT1N0M0 breast carcinoma. Cancer. 1999, 85 (10): 2183-2189. 10.1002/(SICI)1097-0142(19990515)85:10<2183::AID-CNCR12>3.0.CO;2-K.CrossRefPubMed
7.
Cavaliere A, Scheibel M, Bellezza G, Colella R, Vitali R, Gori S, Aristei C, Rulli A, Sidoni A: Ductal carcinoma in situ with microinvasion: clinicopathologic study and biopathologic profile. Pathol Res Pract. 2006, 202 (3): 131-135. 10.1016/j.prp.2006.01.001.CrossRefPubMed
8.
Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V: Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol. 2007, 25 (31): 4952-4960. 10.1200/JCO.2006.08.0499.CrossRefPubMed
9.
Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL, Wolmark N: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst. 2001, 93 (2): 112-120. 10.1093/jnci/93.2.112.CrossRefPubMed
10.
Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA: Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol. 2004, 22 (9): 1630-1637. 10.1200/JCO.2004.09.070.CrossRefPubMed
11.
Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW: An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008, 107 (3): 309-330. 10.1007/s10549-007-9556-1.CrossRefPubMed
12.
Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Viale G, Renne G, Casadio C, Veronesi P, Intra M, Torrisi R, et al: Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. Ann Oncol. 2004, 15 (11): 1633-1639. 10.1093/annonc/mdh434.CrossRefPubMed
13.
Choi DH, Shin DB, Lee MH, Lee DW, Dhandapani D, Carter D, King BL, Haffty BG: A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer. 2003, 98 (8): 1587-1595. 10.1002/cncr.11703.CrossRefPubMed
14.
Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS: Spectrum of breast cancer in Asian women. World J Surg. 2007, 31 (5): 1031-1040. 10.1007/s00268-005-0585-9.CrossRefPubMed
15.
Cancer AJCo: AJCC Cancer Staging Manual. 2002, New York, NY: Springer, 6
16.
Jung SY, Han W, Lee JW, Ko E, Kim E, Yu JH, Moon HG, Park IA, Oh DY, Im SA, et al: Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol. 2009, 16 (5): 1112-1121. 10.1245/s10434-009-0334-7.CrossRefPubMed
17.
Stierer M, Rosen HR, Weber R, Marczell A, Kornek GV, Czerwenka E: Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. Surg Gynecol Obstet. 1992, 175 (2): 151-160.PubMed
18.
Leitner SP, Swern AS, Weinberger D, Duncan LJ, Hutter RV: Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0). Cancer. 1995, 76 (11): 2266-2274. 10.1002/1097-0142(19951201)76:11<2266::AID-CNCR2820761114>3.0.CO;2-T.CrossRefPubMed
19.
Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkanen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J: Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 2003, 9 (3): 923-930.PubMed
20.
Trudeau ME, Pritchard KI, Chapman JA, Hanna WM, Kahn HJ, Murray D, Sawka CA, Mobbs BG, Andrulis I, McCready DR, et al: Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Res Treat. 2005, 89 (1): 35-45. 10.1007/s10549-004-1368-y.CrossRefPubMed
21.
Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S: Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol. 1995, 13 (5): 1144-1151.PubMed
22.
Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R, Viale G, Pruneri G, Veronesi P, Luini A, et al: Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol. 2006, 17 (10): 1497-1503. 10.1093/annonc/mdl145.CrossRefPubMed
23.
Ponzone R, Montemurro F, Maggiorotto F, Robba C, Gregori D, Jacomuzzi ME, Kubatzki F, Marenco D, Dominguez A, Biglia N, et al: Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. Ann Oncol. 2006, 17 (11): 1631-1636. 10.1093/annonc/mdl296.CrossRefPubMed
24.
Railo M, Lundin J, Haglund C, von Smitten K, Nordling S: Ki-67, p53, ER receptors, ploidy and S phase as long-term prognostic factors in T1 node-negative breast cancer. Tumour Biol. 2007, 28 (1): 45-51. 10.1159/000097702.CrossRefPubMed
25.
Rakkhit RBK, Peintinger F, Cardoso F, Hanrahan EO, Litton JK, Sahin A, Larsimont D, Meric-Bernstam F, Buchholz TA, Valero V, Theriault RL, Piccart M, Ravdin P, Hortobagyi GN, Gonzalez-Angulo AM: Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. Abstract. The 31th CTRC-AACR San Antonio Breast Cancer Symposium. 2008
26.
Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W: Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. J Clin Oncol. 2007, 25 (17): 2360-2368. 10.1200/JCO.2006.10.3754.CrossRefPubMed
27.
Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. CA Cancer J Clin. 1997, 47 (1): 5-27. 10.3322/canjclin.47.1.5.CrossRefPubMed
28.
Tovey SM, Brown S, Doughty JC, Mallon EA, Cooke TG, Edwards J: Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer. 2009, 100 (5): 680-683. 10.1038/sj.bjc.6604940.CrossRefPubMedPubMedCentral
29.
Torrisi R, Rotmensz N, Bagnardi V, Viale G, Curto BD, Dell'orto P, Veronesi P, Luini A, D'Alessandro C, Cardillo A, et al: HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer. 2007, 43 (16): 2339-2344. 10.1016/j.ejca.2007.07.033.CrossRefPubMed
30.
Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K: Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res. 16 (3): 876-887. 10.1158/1078-0432.CCR-09-1532.
31.
Menard S, Balsari A, Tagliabue E, Camerini T, Casalini P, Bufalino R, Castiglioni F, Carcangiu ML, Gloghini A, Scalone S, et al: Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann Oncol. 2008, 19 (10): 1706-1712. 10.1093/annonc/mdn369.CrossRefPubMed
32.
Louwman WJ, van Beek MW, Schapers RF, Nolthenius-Puylaert MB, van Diest PJ, Roumen RM, Coebergh JW: Long-term survival of T1 and T2 lymph node-negative breast cancer patients according to Mitotic Activity Index: a population-based study. Int J Cancer. 2006, 118 (9): 2310-2314. 10.1002/ijc.21623.CrossRefPubMed
33.
Baak JP, van Diest PJ, Janssen EA, Gudlaugsson E, Voorhorst FJ, van der Wall E, Vermorken JB: Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. Ann Oncol. 2008, 19 (4): 649-654. 10.1093/annonc/mdm535.CrossRefPubMed
34.
Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, et al: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009, 27 (8): 1168-1176. 10.1200/JCO.2008.18.1024.CrossRefPubMedPubMedCentral
Metadata
Title
Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less
Authors
Ji Hyun Kwon
Yu Jung Kim
Keun-Wook Lee
Do-Youn Oh
So Yeon Park
Jee Hyun Kim
Eui Kyu Chie
Sung-Won Kim
Seock-Ah Im
In-Ah Kim
Tae-You Kim
In Ae Park
Dong-Young Noh
Yung-Jue Bang
Sung Whan Ha
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-557

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists

Research article

Seladin-1 expression is regulated by promoter methylation in adrenal cancer

Research article

Serum vitamin D levels and survival of patients with colorectal cancer: Post-hoc analysis of a prospective cohort study

Case report

Monozygotic twins with Neurofibromatosis type 1, concordant phenotype and synchronous development of MPNST and metastasis

Case report

Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report

Research article

Benign mammary epithelial cells enhance the transformed phenotype of human breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits